ISRCTN13275753已完成不适用
Randomised placebo controlled trial of antihypertensive agents for the prevention of cardiovascular complications of hypertensio
Sponsor not defined - Record provided by the Medical Research Council (UK)0 个研究点目标入组 4,396 人开始时间: 2005年9月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 4,396
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Men and women aged 65-74 at recruitment in 226 general practices in the Medical Research Council's General Practice Research Framework. Systolic blood pressure 160-209 mmHg and diastolic pressure less than 115 mmHg.
排除标准
- •Secondary hypertension; already on antihypertensive treatment; accepted indication for antihypertensive treatment; myocardial infarction or stroke within previous three months; impaired renal function; presence of angina, intermittent claudication, diabetes, gout, bronchial asthma, serious intercurrent disease including malignant hypertension.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignanciesMedDRA version: 17.1Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003812-36-ESMorphotek Inc214
进行中（未招募）
不适用
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First RelapsePrima recidiva di carcinoma ovarico epiteliale non mucinoso platino-sensibile incluso carcinoma peritoneale primario o tumore delle tube di falloppioMedDRA version: 14.1Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005872-29-ITEisai Limited1,080
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignanciesMedDRA version: 20.0Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003812-36-GBEisai Limited210
进行中（未招募）
不适用
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 14.0Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005872-29-ATEisai Limited1,080
进行中（未招募）
1 期
A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System AtrophyMedDRA version: 21.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disordersMultiple System AtrophyEUCTR2022-000336-28-DETakeda Development Center Americas, Inc.138